327
Views
9
CrossRef citations to date
0
Altmetric
Omalizumab treatment in patients with severe chronic spontaneous urticaria: consideration on efficacy from real-life experiences

Chronic urticaria in a child affected by atopic dermatitis: effective treatment with omalizumab

, &
Pages 17-19 | Received 20 Feb 2018, Accepted 27 Oct 2018, Published online: 03 Jan 2019

References

  • Sarbjit SS. Chronic spontaneous urticaria: etiology and pathogenesis. Immunol Allergy Clin North Am. 2014;34:33–52.
  • Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy. 2009;39:777–787.
  • Vonakis BM, Saini SS. New concepts in chronic urticaria. Curr Opin Immunol. 2008;20:709–716.
  • Brodell LA, Beck LA, Saini SS. Pathophysiology of chronic urticaria. Ann Allergy Asthma Immunol. 2008;100:291–297.
  • Wedi B, Raap U, Wieczorek D, et al. Urticaria and infections. Allergy Asthma Clin Immunol. 2009;5:10
  • Kozel MM, Mekkes JR, Bossuyt PM, et al. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol. 2001;45:387–391.
  • Van der Valk PG, Moret G, Kiemeney LA. The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre. Br J Dermatol. 2002;146:110–113.
  • Chang TW, Chen C, Lin CJ, et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2015;135:337–342.
  • Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update. Allergy. 2018;73:1393–1414.
  • Lyons JJ, Milner JD, Stone KD. Atopic dermatitis in children: clinical features, pathophysiology and treatment. Immunol Allergy Clin North Am. 2015;35:161–183.
  • Fernández-Antón Martínez MC, Leis-Dosil V, Alfageme-Roldán F, et al. Omalizumab for the treatment of atopic dermatitis. Actas Dermosifiliogr. 2012;103:624–628.
  • Iyengar SR, Hoyte EG, Loza A, et al. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol. 2013;162:89–93.
  • Chan S, Cornelius V, Chen T, et al. Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT): the role of anti-IgE in severe paediatric eczema: study protocol for a randomised controlled trial. Trials. 2017;18:136.
  • Chen T, Chan S, Lack G, et al. The role of anti-IgE (omalizumab/Xolair) in the management of severe recalcitrant paediatric atopic eczema (ADAPT): statistical analysis plan. Trials. 2017;18:231.
  • Holm J, Agner T, Sand C, et al. Omalizumab for atopic dermatitis: case series and a systematic review of the literature. Int J Dermatol. 2017;56:18–26.
  • Snast I, Reiter O, Hodak E, et al. Are biologics efficacious in atopic dermatitis? A systematic review and meta-analysis. Am J Clin Dermatol. 2018;19:145–165.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.